Shareholders' Equity and Capital Stock - Schedule of outstanding warrants (Details) - USD ($) $ / shares in Units, $ in Thousands |
9 Months Ended | |
|---|---|---|
Sep. 30, 2025 |
Dec. 31, 2024 |
|
| Shareholders Equity and Capital Stock | ||
| Exercise price | $ 1.5 | $ 1.5 |
| Number of warrants | 38,526,000 | 39,041,000 |
| Weighted- average remaining contractual life (years) | 4 months 24 days | |
| Aggregate intrinsic value | $ 5,586,270 | |
| Exercise price $1.50 | ||
| Shareholders Equity and Capital Stock | ||
| Exercise price | $ 1.5 | |
| Number of warrants | 38,526,000 | |
| Weighted- average remaining contractual life (years) | 4 months 24 days | |
| Aggregate intrinsic value | $ 5,586,270 | |
| Expiry | Feb. 21, 2026 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Number of warrants or rights outstanding. No definition available.
|
| X | ||||||||||
- Definition Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|